News & Perspective

(CIDRAP News) – The first wave of H1N1 vaccine will probably consist of 3.4 million doses of MedImmune's nasal-spray product and is likely to reach providers the first week in October, federal health officials said today.

(CIDRAP News) – For children and adolescents with asthma, the intranasal influenza vaccine FluMist was as safe as and more effective than an injectable vaccine in a phase 3 trial of young people aged 6 to about 17 years.

The study, which involved 2,229 children at 145 sites in 12 European countries and Israel, was published in the October issue of The Pediatric Infectious Disease Journal.